U.S. markets closed
  • S&P Futures

    4,137.75
    -15.75 (-0.38%)
     
  • Dow Futures

    32,999.00
    -156.00 (-0.47%)
     
  • Nasdaq Futures

    14,015.75
    -19.25 (-0.14%)
     
  • Russell 2000 Futures

    2,218.60
    -12.00 (-0.54%)
     
  • Crude Oil

    72.29
    +0.65 (+0.91%)
     
  • Gold

    1,773.70
    +4.70 (+0.27%)
     
  • Silver

    25.99
    +0.02 (+0.06%)
     
  • EUR/USD

    1.1874
    +0.0008 (+0.07%)
     
  • 10-Yr Bond

    1.4500
    -0.0610 (-4.04%)
     
  • Vix

    20.70
    +2.95 (+16.62%)
     
  • GBP/USD

    1.3815
    +0.0006 (+0.05%)
     
  • USD/JPY

    110.0220
    -0.1280 (-0.12%)
     
  • BTC-USD

    35,145.86
    -282.87 (-0.80%)
     
  • CMC Crypto 200

    872.06
    -67.88 (-7.22%)
     
  • FTSE 100

    7,017.47
    -135.96 (-1.90%)
     
  • Nikkei 225

    27,952.32
    -1,011.76 (-3.49%)
     

Aldeyra to Participate in Citi’s 15th Annual BioPharma Virtual Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and Chief Executive Officer Todd C. Brady, M.D., Ph.D., will participate in an ophthalmology panel discussion during Citi’s 15th Annual BioPharma Virtual Conference, taking place September 8-11, 2020. In addition, Aldeyra’s senior management will host one-on-one meetings at the conference.

Panel Details

Title: Seeing 20/20 in 2020
Date: Thursday, September 10, 2020
Time: 9:50 a.m. ET

A live webcast of the panel discussion will be available on the investor relations page of the company’s corporate website at https://ir.aldeyra.com. After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for 90 days.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200903005190/en/

Contacts

Corporate Contact:
David McMullin
Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 218
dmcmullin@aldeyra.com

Investor & Media Contact:
Scott Solomon
Sharon Merrill Associates, Inc.
Tel: 617-542-5300
ALDX@investorrelations.com